Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cabaletta Bio, Inc. Director's Dealing 2025

May 20, 2025

33628_dirs_2025-05-19_f3f76023-d592-4e1f-9c4f-c8a323a4dd3d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cabaletta Bio, Inc. (CABA)
CIK: 0001759138
Period of Report: 2025-05-19

Reporting Person: Chang David J. (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-05-19 Stock Option (Right to Buy) $6.3 D 185709 Disposed 2029-06-23 Common Stock (185709) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 185709 Acquired 2029-06-23 Common Stock (185709) Direct
2025-05-19 Stock Option (Right to Buy) $11 D 48836 Disposed 2029-10-23 Common Stock (48836) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 48836 Acquired 2029-10-23 Common Stock (48836) Direct
2025-05-19 Stock Option (Right to Buy) $14.94 D 38238 Disposed 2030-02-28 Common Stock (38238) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 38238 Acquired 2030-02-28 Common Stock (38238) Direct
2025-05-19 Stock Option (Right to Buy) $11.47 D 113500 Disposed 2031-02-28 Common Stock (113500) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 113500 Acquired 2031-02-28 Common Stock (113500) Direct
2025-05-19 Stock Option (Right to Buy) $3.21 D 135000 Disposed 2032-01-17 Common Stock (135000) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 135000 Acquired 2032-01-17 Common Stock (135000) Direct
2025-05-19 Stock Option (Right to Buy) $11.09 D 150000 Disposed 2033-01-17 Common Stock (150000) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 150000 Acquired 2033-01-17 Common Stock (150000) Direct
2025-05-19 Stock Option (Right to Buy) $23.97 D 130000 Disposed 2034-02-28 Common Stock (130000) Direct
2025-05-19 Stock Option (Right to Buy) $1.92 A 130000 Acquired 2034-02-28 Common Stock (130000) Direct

Footnotes

F1: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

F3: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.